Tag Archive for: Adcetris

The company stated that Adcetris, extended survival in patients with the most common type of lymphoma in a late-stage study, bolstering efforts to expand the use of the treatment gained through its $43 billion purchase of Seagen.

Already approved in later stage and high-risk cHL, the goal of ongoing Adcetris studies is to “develop curative treatments that improve survival while also reducing toxicity,” Jeremy Abramson, director of the Jon and Jo Ann Hagler Center for Lymphoma at Massachusetts General Hospital and principal investigator for the Phase II trial, said in a statement.  

Data from a new head-to-head study showed BMS’ Opdivo induced better progression-free survival among Hodgkin’s lymphoma patients than Seagen’s Adcetris.

Under a new collaborative research agreement, Astellas Pharma is turning to an interesting choice of partner to develop a novel antibody-drug conjugate platform for oncology therapeutics. Tuesday, the Tokyo-based biopharma announced a collaboration with tech giant Sony Corporation.

Following its failed deal with Merck last year, Seagen has a new suitor. The Seattle-based company is in talks with Pfizer over a potential acquisition, The Wall Street Journal reported Sunday evening, citing people familiar with the matter.

The Washington-based biotech is focusing on upcoming label expansions and its promising pipeline.

The three costliest therapies under Medicare health insurance in the United States saw price hikes in 2020 but there was not enough evidence of new clinical benefits, the Institute for Clinical and Economic Review (ICER) said on Tuesday.

Seagen is on a roll this week. After naming David R. Epstein as its new CEO, the Washington-based biotech announced that Adcetris (brentuximab vedotin) has been given FDA approval for the treatment of children aged two years and above with high-risk classical Hodgkin lymphoma. 

Merck’s bid to buy the cancer-focused Seagen has hit a roadblock after the two companies failed to agree on a price, according to a Bloomberg report published Friday, citing sources familiar with the matter.